Avadel Pharmaceuticals Stock Forecast, Price & News

Avadel Pharmaceuticals (NASDAQ:AVDL) Frequently Asked Questions

Is Avadel Pharmaceuticals a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Avadel Pharmaceuticals in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Avadel Pharmaceuticals stock.
View analyst ratings for Avadel Pharmaceuticals or view top-rated stocks.

How has Avadel Pharmaceuticals' stock price been impacted by COVID-19 (Coronavirus)?

Avadel Pharmaceuticals' stock was trading at $7.99 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, AVDL shares have increased by 11.8% and is now trading at $8.93.
View which stocks have been most impacted by COVID-19.

Are investors shorting Avadel Pharmaceuticals?

Avadel Pharmaceuticals saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 4,780,000 shares, an increase of 29.9% from the October 31st total of 3,680,000 shares. Based on an average daily volume of 704,400 shares, the days-to-cover ratio is currently 6.8 days. Currently, 9.4% of the company's stock are sold short.
View Avadel Pharmaceuticals' Short Interest.

When is Avadel Pharmaceuticals' next earnings date?

Avadel Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, March 8th 2022.
View our earnings forecast for Avadel Pharmaceuticals.

How were Avadel Pharmaceuticals' earnings last quarter?

Avadel Pharmaceuticals plc (NASDAQ:AVDL) posted its quarterly earnings results on Monday, November, 8th. The company reported ($0.38) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.38). During the same quarter in the previous year, the company posted ($0.20) earnings per share.
View Avadel Pharmaceuticals' earnings history.

What price target have analysts set for AVDL?

3 equities research analysts have issued 1 year price objectives for Avadel Pharmaceuticals' shares. Their forecasts range from $16.00 to $17.00. On average, they expect Avadel Pharmaceuticals' share price to reach $16.50 in the next year. This suggests a possible upside of 84.8% from the stock's current price.
View analysts' price targets for Avadel Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Avadel Pharmaceuticals' key executives?

Avadel Pharmaceuticals' management team includes the following people:

• Gregory J. Divis, Chief Executive Officer & Director
• Thomas S. McHugh, Chief Financial & Accounting Officer
• Jennifer Gudeman, Vice President-Medical & Clinical Affairs
• Dhiren D'silva, Vice President-Irish & European Operations
• Jason Vaughn, Senior Vice President-Technical Operations

Who are some of Avadel Pharmaceuticals' key competitors?

Some companies that are related to Avadel Pharmaceuticals include Harmony Biosciences (HRMY), Nektar Therapeutics (NKTR), Nuvation Bio (NUVB), Taro Pharmaceutical Industries (TARO), Trillium Therapeutics (TRIL), Agios Pharmaceuticals (AGIO), Dynavax Technologies (DVAX), Avid Bioservices (CDMO), Turning Point Therapeutics (TPTX), Ironwood Pharmaceuticals (IRWD), Global Blood Therapeutics (GBT), Enanta Pharmaceuticals (ENTA), Atai Life Sciences (ATAI), Morphic (MORF) and Travere Therapeutics (TVTX).
View all of AVDL's competitors.

What other stocks do shareholders of Avadel Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Avadel Pharmaceuticals investors own include Intelsat (I), Bank of America (BAC), Fossil Group (FOSL), Ciena (CIEN), AMC Entertainment (AMC), Chaarat Gold (CGH), Associated British Foods (ABF), Apollo Global Management (APO), Amarin (AMRN) and Cypress Semiconductor (CY).

What is Avadel Pharmaceuticals' stock symbol?

Avadel Pharmaceuticals trades on the NASDAQ under the ticker symbol "AVDL."

Who are Avadel Pharmaceuticals' major shareholders?

Avadel Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Cowen AND Company LLC (4.31%), Gendell Jeffrey L (3.51%), Renaissance Technologies LLC (1.46%), Janus Henderson Group PLC (1.38%), Asymmetry Capital Management L.P. (0.81%) and Morgan Stanley (0.72%). Company insiders that own Avadel Pharmaceuticals stock include Eric J Ende, Gregory J Divis, Linda Palczuk, Mark Anthony Mccamish, Sandra L Hatten and Thomas S Mchugh.
View institutional ownership trends for Avadel Pharmaceuticals.

Which major investors are selling Avadel Pharmaceuticals stock?

AVDL stock was sold by a variety of institutional investors in the last quarter, including Iridian Asset Management LLC CT, Tri Locum Partners LP, Deutsche Bank AG, Keel Point LLC, Citadel Advisors LLC, Renaissance Technologies LLC, Atom Investors LP, and Eaton Vance Management.
View insider buying and selling activity for Avadel Pharmaceuticals or view top insider-selling stocks.

Which major investors are buying Avadel Pharmaceuticals stock?

AVDL stock was bought by a variety of institutional investors in the last quarter, including BioImpact Capital LLC, Asymmetry Capital Management L.P., Janus Henderson Group PLC, Morgan Stanley, Cowen AND Company LLC, Gendell Jeffrey L, Citigroup Inc., and Cubist Systematic Strategies LLC. Company insiders that have bought Avadel Pharmaceuticals stock in the last two years include Eric J Ende, Gregory J Divis, Linda Palczuk, Mark Anthony Mccamish, and Thomas S Mchugh.
View insider buying and selling activity for Avadel Pharmaceuticals or or view top insider-buying stocks.

How do I buy shares of Avadel Pharmaceuticals?

Shares of AVDL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Avadel Pharmaceuticals' stock price today?

One share of AVDL stock can currently be purchased for approximately $8.93.

How much money does Avadel Pharmaceuticals make?

Avadel Pharmaceuticals has a market capitalization of $523.48 million and generates $22.33 million in revenue each year. The company earns $7.03 million in net income (profit) each year or ($1.13) on an earnings per share basis.

How many employees does Avadel Pharmaceuticals have?

Avadel Pharmaceuticals employs 2,020 workers across the globe.

When was Avadel Pharmaceuticals founded?

Avadel Pharmaceuticals was founded in 2015.

What is Avadel Pharmaceuticals' official website?

The official website for Avadel Pharmaceuticals is www.avadel.com.

Where are Avadel Pharmaceuticals' headquarters?

Avadel Pharmaceuticals is headquartered at 10 EARLSFORT TERRACE, DUBLIN L2, D02.

How can I contact Avadel Pharmaceuticals?

Avadel Pharmaceuticals' mailing address is 10 EARLSFORT TERRACE, DUBLIN L2, D02. The company can be reached via phone at (531) 485-1200, via email at [email protected], or via fax at 353-1526-1077.